Table 3 Characteristics of patients with appropriate therapy receiving monotherapy or combination therapy
|  | Monotherapy (n = 96) | Combination Therapy (n = 51) | p value |
|---|---|---|---|
Age, years, median (IQR) | 66(50.25−78) | 66(57.5–80) | 0.151 |
Male sex | 41(42.71%) | 28(54.90%) | 0.159 |
Comorbidities | Â | Â | Â |
 Cardiovascular disease | 25(26.04%) | 16(31.37%) | 0.493 |
 Diabetes | 32(33.335) | 20(39.22%) | 0.478 |
 Chronic kidney disease | 13(13.54%) | 7(13.73%) | 0.975 |
 Chronic liver disease | 2(2.08%) | 2(3.92%) | 0.514 |
 COPD | 0 | 3(5.88%) | 0.016 |
 Solid cancer | 14(14.58%) | 6(11.76%) | 0.635 |
 Immunosuppression | 5(5.21%) | 6(11.76%) | 0.15 |
Site of infection | Â | Â | Â |
 Pulmonary | 19(19.79%) | 14(27.45%) | 0.289 |
 Intra-abdominal | 24(25%) | 12(23.53%) | 0.844 |
 Vascular catheter | 2(2.08%) | 5(9.8%) | 0.036 |
 Genitourinary | 33(34.38%) | 8(15.69%) | 0.016 |
 Skin or soft tissue | 7(7.29%) | 1(1.96%) | 0.175 |
 Bone or Joint | 5(5.21%) | 9(17.65%) | 0.014 |
 Other | 6(6.25%) | 2(3.92%) | 0.554 |
Charlson comorbidity index score | 1(0–2) | 1(0–2) | 0.757 |
Pitt bacteraemia score | 1(0–2) | 2(1–4) | 0.2 |
SOFA Score on Culture Day | 1.5(0–5) | 3(1–10) | 0.005 |
APACHE II score | 16(11.5–20) | 16(11.75–21.25) | 0.2 |
ICU admission | 41(42.71%) | 36(70.59%) | 0.001 |
Length of ICU stay after BSI, days | 7(4.5–11.5) | 18(8–31) | <0.001 |
Hospital length of stay after BSI, days | 12(8−16.5) | 16(12–28) | 0.362 |
Type of acquisition | Â | Â | 0.467 |
 Healthcare-associated | 11(11.46%) | 8(15.69%) |  |
 Nosocomial | 85(88.54%) | 43(84.31%) |  |
Mechanical ventilation | 10(10.42%) | 15(29.41%) | 0.004 |
AKI | 6(6.25%) | 6(11.76%) | 0.245 |
Septic shock | 25(26.04%) | 23(45.10%) | 0.019 |